Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A [amibegron] (350 mg q12) in elderly patients with major depressive disorder (MDD).

Next Previous
X
Search
Trial Profile

An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A [amibegron] (350 mg q12) in elderly patients with major depressive disorder (MDD).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amibegron (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms ZEPHIR
  • Sponsors Sanofi

    • Most Recent Events

    • 12 Jul 2011 Additional trial location (France) added as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source added and integrated (European Clinical Trials Database, EudraCT2005-005597-67).
    • 13 Nov 2008 End dates added, identifier added.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top